| 1 |
35061161 | Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling. | 2022 Jun |
7 |
| 2 |
35342886 | Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. | 2022 Feb |
1 |
| 3 |
33509019 | Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. | 2021 May |
4 |
| 4 |
33556367 | Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. | 2021 Apr 1 |
1 |
| 5 |
34210056 | Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis. | 2021 Jun 29 |
5 |
| 6 |
34498315 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. | 2021 Oct |
1 |
| 7 |
34638547 | Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison. | 2021 Sep 22 |
4 |
| 8 |
32272615 | Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. | 2020 Apr 7 |
1 |
| 9 |
32586526 | Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. | 2020 Jul |
1 |
| 10 |
32938720 | Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism. | 2020 Nov |
6 |
| 11 |
30472588 | In vivo phenotyping of cytochrome 450 isoforms involved in the metabolism of anti-HIV and anti-tubercular drugs in human using cocktail approach: An LC-MS/MS analysis. | 2019 Feb 5 |
1 |
| 12 |
31058419 | Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. | 2019 Oct |
1 |
| 13 |
32186616 | [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients]. | 2019 Dec |
4 |
| 14 |
29746595 | Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30. | 2018 |
1 |
| 15 |
27934636 | Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor. | 2017 Feb |
2 |
| 16 |
28805981 | Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product. | 2017 Aug |
2 |
| 17 |
28972767 | Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. | 2017 Oct 17 |
1 |
| 18 |
26551762 | The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes. | 2016 Jun |
7 |
| 19 |
26806573 | Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. | 2016 Mar 2 |
1 |
| 20 |
27216792 | Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. | 2016 |
1 |
| 21 |
27287328 | Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro. | 2016 |
1 |
| 22 |
27474842 | Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen? | 2016 Sep 1 |
2 |
| 23 |
25977991 | Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. | 2015 Jun |
2 |
| 24 |
25994031 | Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. | 2015 Aug |
1 |
| 25 |
26233334 | Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation? | 2015 Oct |
1 |
| 26 |
26669712 | P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects. | 2015 Dec |
2 |
| 27 |
23844998 | Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. | 2014 Mar |
4 |
| 28 |
24986093 | Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. | 2014 Sep |
15 |
| 29 |
25075423 | Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient. | 2014 |
4 |
| 30 |
25303293 | Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. | 2014 Aug |
6 |
| 31 |
23118328 | Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. | 2013 Jan |
6 |
| 32 |
24800477 | [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. | 2013 |
1 |
| 33 |
21870106 | Repeated administration of berberine inhibits cytochromes P450 in humans. | 2012 Feb |
1 |
| 34 |
22294058 | Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. | 2012 Jul |
1 |
| 35 |
22483397 | High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. | 2012 May 1 |
1 |
| 36 |
22735459 | Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. | 2012 Sep |
10 |
| 37 |
23093260 | Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. | 2012 |
4 |
| 38 |
21182487 | Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. | 2011 |
1 |
| 39 |
21321060 | CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. | 2011 May |
5 |
| 40 |
21332946 | Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. | 2011 Aug |
2 |
| 41 |
21666702 | Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. | 2011 Jul |
2 |
| 42 |
21841812 | Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. | 2011 Oct |
7 |
| 43 |
19715737 | Polymorphisms of human cytochrome P450 2C9 and the functional relevance. | 2010 Dec 5 |
2 |
| 44 |
19903527 | Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. | 2010 Jan 31 |
2 |
| 45 |
20405111 | Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. | 2010 Aug |
3 |
| 46 |
20668444 | Clinically significant CYP2C inhibition by noscapine but not by glucosamine. | 2010 Sep |
1 |
| 47 |
19221727 | Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. | 2009 Jun |
4 |
| 48 |
19541829 | Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. | 2009 Sep |
3 |
| 49 |
19593208 | CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. | 2009 Oct |
4 |
| 50 |
19604036 | Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. | 2009 Oct |
8 |